EU approves H1N1 vaccines from Novartis and GSK, Baxter's jab gets positive opinion
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing authorisation to two adjuvanted mock-up vaccines against pandemic H1N1, Novartis's Focetria and GlaxoSmithKline's Pandemrix.